TLR Inhibitors

Catalog No.	Product Name	Information
E5893	MTT5	MTT5 is an agonist of TLR7 that activates dendritic cells and CD8⁺ T cells, enhancing immune responses in the tumor microenvironment. When linked to an ADC, it enhances antitumor efficacy through combined immune stimulation and cytotoxicity.
E5909	CL075	CL075 (3M002) is a selective agonist of TLR8 with immunomodulatory properties. It primes human neutrophils by activating signaling pathways, including p47phox phosphorylation and p38MAPK, leading to enhanced reactive oxygen species (ROS) production and contributing to immune defense.
E5778	CU-CPT 4a	CU-CPT 4a (TLR3-IN-1) is a potent small molecule antagonist of TLR3 with an IC50 of 3.44 µM that also inhibits TLR3/dsRNA-mediated signaling, including TNF-α and IL-1β expression. It is a valuable tool for studying protein-RNA complexes.
E6040	Imiquimod maleate	Imiquimod maleate (R 837 maleate) is a small-molecule salt derivative of maleic acid, isolated from the Imiquimod free base and is an immune response modifier, a potent and selective agonist of toll like receptor 7 (TLR7), an antagonist of adenosine A₂A receptor with a Ki of 2.16 μM, and an inhibitor of adenylyl cyclase activity, inducing antiviral proteins like cystatin A. It exhibits strong antitumoral and antiviral efficacy, making it effective for conditions such as COVID 19, HPV warts, molluscum contagiosum, actinic keratosis, basal and squamous cell carcinoma, Bowen's disease, and vulvar intraepithelial neoplasia.
E5812	AT791	AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.
≡ All TLR Inhibitors

New TLR Inhibitors